SCYNEXIS INC SCYX
SCYNEXIS, Inc. is dedicated to advancing innovative solutions for severe rare diseases, with our lead program in the treatment and prevention of difficult-to-treat and drug-resistant fungal infections. We are developing our proprietary antifungal platform "fungerps", a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a broad range of human fungal pathogens such as Candida and Aspergillus genera, including multidrug-resistant strains, as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and most common mucorales species.
Ibrexafungerp is the first representative of this novel class of antifungals and was approved by the U.S. Food and Drug Administration (FDA) as BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (VVC) and for the reduction in the incidence of recurrent vulvovaginal candidiasis (rVVC) in 2021 and 2022, respectively. Ibrexafungerp was licensed to GSK in May 2023.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.6M | $3.7M | $140.1M | $5.1M | $13.2M | $0 | $121.0K | $257.0K | $257.0K | $257.0K |
| R&D | $22.3M | $26.4M | $30.9M | $27.3M | $23.8M | $36.5M | $38.4M | $21.6M | $18.3M | $20.1M |
| SG&A | $14.4M | $14.5M | $20.9M | $63.0M | $49.9M | $14.6M | $10.6M | $8.7M | $8.3M | $8.0M |
| Total operating expenses | $36.7M | $40.9M | $67.5M | $90.8M | $74.0M | $51.1M | $49.0M | $30.2M | $26.6M | $28.1M |
| Operating income | -$16.1M | -$37.1M | $72.7M | -$85.8M | -$60.8M | -$51.1M | -$48.9M | -$30.0M | -$26.3M | -$27.8M |
| Interest expense | $173.0K | $828.0K | $3.1M | $5.2M | $2.7M | $1.2M | $986.0K | $1.6M | $1.5M | $351.0K |
| Pre-tax income | -$8.6M | -$21.1M | $67.2M | -$67.5M | -$36.0M | -$58.3M | -$53.7M | -$19.2M | -$25.1M | -$30.0M |
| Income tax | $0 | $151.0K | $138.0K | $4.7M | $3.1M | $3.1M | $0 | $6.7M | $0 | $0 |
| Net income | -$8.6M | -$21.3M | $67.0M | -$62.8M | -$32.9M | -$55.2M | -$53.7M | -$12.5M | -$25.1M | -$30.0M |
| EPS, basic | -0.17 | -0.44 | 1.40 | -1.47 | -1.25 | — | — | — | — | -1.58 |
| EPS, diluted | -0.17 | -0.44 | 1.39 | -1.47 | -1.25 | — | — | — | — | -1.58 |
| Shares, diluted (wtd. avg.) | 49.9M | 48.5M | 48.4M | 42.6M | 26.4M | — | — | — | — | 19.0M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $21.3M | $16.1M | $34.6M | $46.0M | $104.7M | $93.3M | $42.2M | $11.8M | $11.5M | $35.7M |
| Short-term investments | $18.8M | $43.2M | $40.3M | $27.7M | $0 | — | — | — | — | $22.9M |
| Receivables | — | — | $0 | $2.1M | $861.0K | $0 | — | — | — | — |
| Inventory | — | — | $0 | $899.0K | $463.0K | $0 | — | — | — | — |
| Total current assets | $40.4M | $72.2M | $102.1M | $79.1M | $109.4M | $98.2M | $52.4M | $51.5M | $45.0M | $59.3M |
| Property, plant and equipment | — | — | — | — | $113.0K | $298.0K | $405.0K | $516.0K | $4.0K | — |
| Other intangibles | — | — | $0 | $408.0K | $1.1M | $408.0K | — | — | — | — |
| Total assets | $59.0M | $90.6M | $128.4M | $87.8M | $119.8M | $102.5M | $57.2M | $53.2M | $45.9M | $59.8M |
| Accounts payable | $2.2M | $4.6M | $7.1M | $5.9M | $7.8M | $4.6M | $7.2M | $3.7M | $3.8M | $2.2M |
| Short-term debt | — | — | — | — | $0 | — | — | $0 | $4.3M | $0 |
| Total current liabilities | $5.7M | $24.1M | $16.3M | $17.6M | $13.6M | $26.4M | $11.0M | $5.9M | $10.1M | $3.7M |
| Long-term debt | — | — | — | — | $34.4M | — | $0 | $15.1M | $10.3M | $14.3M |
| Total liabilities | $9.7M | $35.6M | $55.5M | $84.6M | $78.6M | $79.8M | $44.3M | $21.9M | $24.4M | $25.0M |
| Retained earnings | -$385.1M | -$376.5M | -$355.2M | -$422.3M | -$359.5M | -$326.6M | -$271.4M | -$217.7M | -$205.2M | -$180.1M |
| Total equity | $49.4M | $55.1M | $73.0M | $3.2M | $41.3M | $22.8M | $12.9M | $31.2M | $21.4M | $34.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.3M | -$24.0M | $60.2M | -$79.9M | -$54.6M | -$49.4M | -$38.1M | -$28.3M | -$24.6M | -$29.4M |
| Depreciation and amortisation | — | — | — | — | $200.0K | $200.0K | $111.0K | $53.0K | $41.0K | $26.0K |
| Stock-based compensation | $2.9M | $3.3M | $2.6M | $3.7M | $2.1M | — | — | — | — | — |
| Capital expenditure | — | — | — | — | $0 | $4.0K | $0 | $565.0K | $2.0K | $27.0K |
| Investing cash flow | $24.3M | $6.2M | -$34.9M | -$27.4M | -$1.2M | $6.5M | $26.2M | -$803.0K | -$9.6M | -$22.5M |
| Financing cash flow | -$14.2M | -$139.0K | -$36.7M | $48.6M | $67.1M | $94.0M | $42.3M | $29.4M | $10.0M | $40.5M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-018207.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $257.0K | $257.0K | $257.0K | $121.0K | $0 | $13.2M | $5.1M | $140.1M | $3.7M | $20.6M |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$30.0M | -$25.1M | -$12.5M | -$53.7M | -$55.2M | -$32.9M | -$62.8M | $67.0M | -$21.3M | -$8.6M |
Recent filings and events
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Charter or fiscal year changed Item 5.03
- Shareholder vote Item 5.07
- Other event Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Material agreement signed Item 1.01
- Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |